Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Coherus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
MHRA’s Authorization for BIOEQ’s Biosimilar in the United Kingdom
Details : CIMERLI™ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI™. Hypersensitivity reactions may manifest as severe intraocular inflammation
Product Name : Cimerli
Product Type : Antibody
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Coherus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Formycon
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive lo...
Product Name : Cimerli
Product Type : Antibody
Upfront Cash : Inapplicable
June 08, 2021
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Formycon
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
